Profound Medical’s TULSA Gains CMS Reimbursement Boost

Profound Medical (TSE:PRN) has released an update.

Profound Medical has announced that its TULSA procedure will receive increased reimbursement under the new CMS rule, highlighting its advantage over other prostate treatment options. With a wider range of treatment settings and increased payment rates, TULSA is poised to redefine patient care with its incision-free approach.

For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.